Read by QxMD icon Read

Hematological Oncology

Zhao-Yun Liu, Meng-Yue Tian, Ling Deng, Ying-Shuai Wang, Rui Xing, Hui Liu, Rong Fu
Multiple myeloma (MM) is malignant tumor with abnormal proliferation of bone marrow plasma cells. The existing clinical tools used to determine treatment response and tumor relapse are limited in sensitivity. We investigated the CD138+ MPs of MM patients to find out whether MPs could provide a novel means to monitor the malignant cells in MM patients. Our study showed that the levels of MPs were significantly elevated in MM patients. The MPs counts in peripheral blood from new diagnosed MM patients was significantly higher than patients in CR and HD...
July 10, 2019: Hematological Oncology
Pan Zhao, Jiayue Qin, Weiyi Liu, Qianze Zhu, Teng Fan, Haiyan Xiao, Juan Wang, Gang Huang, Hu Xiaomei
No abstract text is available yet for this article.
July 10, 2019: Hematological Oncology
Barbara Kiesewetter, Wolfgang Lamm, Ortrun Neuper, Marius E Mayerhoefer, Ingrid Simonitsch-Klupp, Markus Raderer
Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with MALT lymphoma. While initial results were promising, there are currently no data on long-term outcome and larger international phase II/III trials on LEN for indolent lymphoma lack specific subgroup analyses. Thus, we have systematically analyzed 50 patients treated with LEN-based therapy (LEN-monotherapy n = 16, R-LEN n = 34) at the Medical University of Vienna 2009-2019 and investigated long-term outcome and relapse patterns...
July 8, 2019: Hematological Oncology
Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, Jalaja Potluri, John Hayslip, Whitney Kirschbrown, Anna Friedel, Rajeev Menon, Ahmed Hamed Salem
The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent (HMA; azacitidine or decitabine) or low-dose cytarabine (LDAC)). A total of 212 patients from the HMA study and 92 patients from the LDAC study were included in the exposure-safety analyses. Those who received at least one dose of venetoclax and had at least one measurable response (201 and 83, in the HMA and LDAC studies, respectively) were included in the exposure-efficacy analyses...
June 28, 2019: Hematological Oncology
Yingjuan Zheng, Chunzhao Yang, Tiansong Liang, Daoke Yang, Zhangsuo Liu
No abstract text is available yet for this article.
May 18, 2019: Hematological Oncology
R Cassin, V Mattiello, M Viltadi, D D'Aliberti, R Piazza, C Gambacorti-Passerini, U Gianelli, A Neri, A Cortelezzi, G Reda
Atypical chronic myeloid leukemia (aCML) is a rare hematological malignancy with dismal prognosis, usually being reported as isolated disease or in association with other myeloid neoplasms. Treatment strategies used for MDS and MPN, as hypomethylating agents (HMA) or kinase inhibitors, may be considered although experience is limited. We biologically studied an old patient affected by aCML unusually mutated for both SETBP1 and CSF3R, with concomitant chronic lymphocytic leukemia (CLL). Decitabine (DCA) therapy carried complete response after fourth cycle and was complicated by hematological toxicities and infections mainly due to the old age and the CLL-related immune deficit...
May 18, 2019: Hematological Oncology
Zhi-Yao Zhang, Yanchen Li, Chuan-Ying Geng, Huixing Zhou, Wen Gao, Wen-Ming Chen
Accumulating studies have focused on circulating microRNAs, which might be potential biomarkers for different malignancies. The aim of this study was to investigate the potential of serum exosomal microRNAs to be novel serum biomarkers for smouldering myeloma or even multiple myeloma. The levels of serum exosomal microRNAs and serum circulating microRNAs were measured in healthy individuals and patients with smouldering myeloma (SMM) (n=20) or multiple myeloma (n=20). Serum exosomal microRNAs and serum circulating microRNAs were extracted from serum, and the expression levels of selected microRNAs were quantified by real-time PCR...
May 18, 2019: Hematological Oncology
Xuhan Zhang, Lu Liu, Shiyong Zhou, Kuo Zhao, Zheng Song, Ge Hu, Tingting Zhang, Yang Li, Lihua Qiu, Lanfang Li, Zhengzi Qian, Bin Meng, Yi Pan, Xiubao Ren, Xianhuo Wang, Huilai Zhang, Kai Fu
Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death-ligand1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphomas (PTCLs) patients. A total of 37 PTCLs patients and 20 healthy volunteers were enrolled. Peripheral blood from patients was collected prior to systemic therapy...
May 10, 2019: Hematological Oncology
Alessandro Andriani, Elena Elli, Giulio Trapè, Nicoletta Villivà, Luana Fianchi, Ambra Di Veroli, Pasquale Niscola, Antonia Centra, Barbara Anaclerico, Guido Montanaro, Vincenza Martini, Andrea Aroldi, Ida Carmosino, Maria Teresa Voso, Massimo Breccia, Marco Montanaro, Roberto Foà, Roberto Latagliata
There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at the standard dosage (75 mg/m2 ). Median time from diagnosis to AP/BP evolution was 92.3 months (IR 29.9 - 180.1). All patients were evaluable for hematologic response: 2 patients (5.2%) died early after AZA initiation, 13 patients (33...
May 3, 2019: Hematological Oncology
Joanna Drozd-Sokołowska, Jan Maciej Zaucha, Tomasz Żółtak, Krzysztof Jamroziak, Olga Grzybowska-Izydorczyk, Magdalena Witkowska, Anna Waszczuk-Gajda, Maciej Kaźmierczak, Andrzej Szczepaniak, Edyta Subocz, Wanda Knopińska-Posłuszny, Jadwiga Hołojda, Anna Kopińska, Iwona Hus, Justyna Rybka, Dariusz Wołowiec, Jacek Kwiatkowski, Kazimierz Hałaburda, Piotr Smolewski, Sebastian Giebel, Wiesław Wiktor-Jędrzejczak
Richter transformation (RT) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to Hodgkin lymphoma (HL) is a rare and unexpected event in the course of the disease and data on this phenomenon is still limited. To better understand the clinical and histological characteristics and the outcomes of HL variant of RT (HvRT) the Polish Lymphoma Research Group performed a nationwide survey which identified 22 patients with histologically proven HvRS diagnosed between 2002 and 2016. There were 16 (73%) males...
April 26, 2019: Hematological Oncology
Francesco Autore, Idanna Innocenti, Francesca Morelli, Federica Sorà, Andrea Corbingi, Luana Fianchi, Marianna Criscuolo, Livio Pagano, Simona Sica, Luca Laurenti
No abstract text is available yet for this article.
April 24, 2019: Hematological Oncology
Tariq I Mughal, Naveen Pemmaraju, Jerald P Radich, Michael W Deininger, Nicole Kucine, Jean-Jacques Kiladjian, Prithviraj Bose, Jason Gotlib, Peter Valent, Chih-Cheng Chen, Tiziano Barbui, Raajit Rampal, Srdan Verstovsek, Steffen Koschmieder, Giuseppe Saglio, Richard A Van Etten
The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management...
April 23, 2019: Hematological Oncology
Gilles Salles
In recent years, many new antibodies, either naked or armed with toxin or radionuclides have been investigated to enhance the field of active agents directed against already identified ("old") targets. This was particularly the case for the antigens CD19 and CD20 but also some other ones. The success of these developments has been variable and underlines the need to better characterize the mode of action of these molecules. Combinations studies of these new agents with other molecules, in particular those with an immunomodulatory potential, are also currently developed with some promising results...
June 2019: Hematological Oncology
Jie Xiong, Weili Zhao
Natural-killer/T cell lymphoma (NKTCL) is the most common extranodal lymphoma with highly aggressive clinical outcome. System biology techniques provide novel insights into the pathogenesis, risk stratification, and clinical management in NKTCL. Comparative genomic hybridization analysis reveal most frequent deletion of chromosome 6q21. Whole-exome sequencing studies identify recurrent somatic gene mutations, involving RNA helicases, tumor suppressors, JAK-STAT pathway molecules, and epigenetic modifiers. Genome-wide association study reports strongest association of HLA-DPB1 rs9277378 with lymphomagenesis...
June 2019: Hematological Oncology
Sattva S Neelapu
Chimeric antigen receptor (CAR) T-cell therapy has the potential to revolutionize the management of B-cell lymphomas and possibly other cancers. Two anti-CD19 CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel, have been approved for the management of relapsed/refractory large B-cell lymphoma after two lines of systemic therapy. Additional trials are ongoing to evaluate these and other CAR T products at earlier stages of the disease course as well as in other lymphomas. While the potential to induce durable remissions with a single CAR T-cell infusion even in patients who are chemorefractory has generated much enthusiasm in the field, practitioners need to familiarize themselves with the unique toxicities associated with these therapies...
June 2019: Hematological Oncology
Werner Kempf, Anne-Katrin Zimmermann, Christina Mitteldorf
Primary cutaneous lymphomas (CL) are the second most common form of extranodal lymphomas. Cutaneous T-cell lymphomas represent the majority. They are classified according to the WHO classification 2017 and the updated WHO-EORTC 2018 published in the fourth edition of the WHO classification for Skin Tumors monograph. Primary cutaneous acral CD8+ T-cell lymphoma and EBV-positive mucocutaneous ulcer have been listed as new provisional entities. Moreover, the histological and genetic spectrum of lymphomatoid papulosis has been expanded...
June 2019: Hematological Oncology
David Sermer, Renier Brentjens
Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment for lymphoid malignancies, especially diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). However, there continue to be significant limitations of this therapy, such as incomplete or nonsustained responses and severe toxicities in a subset of patients. Furthermore, expanding the role of CAR T-cell therapy to new disease types is an important next step. In this review, we will highlight landmark trials for anti-CD19 CAR T cells and first-in-human trials of novel CARs, as well as discuss promising innovative CAR designs that are still undergoing preclinical development...
June 2019: Hematological Oncology
Ann S LaCasce
Although the majority of patients with Hodgkin lymphoma are cured with initial therapy, 10% to 15% of patients with early stage disease and 15% to 30% of patients with advanced disease have primary refractory or relapsed lymphoma. For younger patients whose disease is sensitive to second-line therapy, more than half of patients will experience long-term disease control with high-dose chemotherapy/autologous stem cell rescue (ASCT). For those patients who are chemotherapy refractory, relapse after, or are ineligible for ASCT, brentuximab vedotin, and checkpoint, inhibitors are highly active, although the majority of patients will ultimately experience recurrent lymphoma...
June 2019: Hematological Oncology
Simon Rule
Mantle Cell Lymphoma is a rare and generally aggressive form of non Hodgkin lymphoma. Our understanding of the pathophysiology of this disease is improving and whilst risk factors are understood, treatments are not yet tailored towards these. The treatment algorithm in the front line is well established for older and younger patients and observation is the norm for a subset of patients although these are not well characterised as yet. In the relapse setting the role of novel agents, especially the BTK inhibitors is becoming established and combination approaches look promising...
June 2019: Hematological Oncology
Wilhelm Woessmann, Leticia Quintanilla-Martinez
Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Both PTFL and pnMZL predominantly affect male adolescents and usually present with localized lymphadenopathy in the head and neck region. The cells within the follicles of PTFL typically show high-grade cytology, IGH monoclonality and lack the t(14;18) chromosomal alteration...
June 2019: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"